Skip to main content
Sinphar Pharmaceutical Co., Ltd. logo

Sinphar Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 1734 ISIN · TW0001734002 TW Manufacturing
Open in API
Filings indexed 1,599 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 1734

About Sinphar Pharmaceutical Co., Ltd.

https://www.sinphar.com

Sinphar Pharmaceutical Co., Ltd. is a vertically integrated pharmaceutical group specializing in the research, development, manufacturing, and distribution of therapeutic medicines, nutraceuticals, and medical cosmetics. Established in 1977, the company produces a diverse range of products, including Western and Chinese pharmaceuticals, specialized oncology drugs, and health supplements. Sinphar operates advanced R&D facilities and an ISO 17025-certified laboratory, leveraging high-precision technology for product innovation and quality assurance. Its business model encompasses proprietary brand management alongside professional OEM and ODM services for international markets. Key areas of expertise include the development of cancer treatments, functional health foods, and medical-grade skincare. Through its global marketing network and dedicated retail counters, Sinphar provides comprehensive healthcare solutions focused on life, health, and technology.

Recent filings

Filing Released Lang Actions
115年第1季財務報告書 — 202601_1734_AI1.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a consolidated financial report for the first quarter (民國115及114年第1季) including full interim financial statements (balance sheet, income statement, cash flows, notes) and an auditor’s review report. It is substantive financial data for a period shorter than a full year (Q1), not merely an announcement or certification. Therefore it fits the definition of an Interim/Quarterly Report. Q1 115
2026-05-15 Chinese
公司基本資料
Regulatory Filings Classification · 82% confidence The document is a generic disclosure of basic corporate and listing information (stock code, industry, contact, address, major business, capital, listing dates, auditor, etc.) provided to Taiwan’s public information observatory. It does not present financial statements, dividend notice, management changes, or any report release. It falls under a general regulatory announcement/fallback category.
2026-05-13 Chinese
115年4月背書保證與資金貸與
Regulatory Filings Classification · 40% confidence The document is a periodic disclosure of the company’s fund lending and guarantee balances provided under Taiwan’s Market Observation Post System (“公開資訊觀測站”). It contains tabular data on loan and guarantee exposures for the current and prior months. It is not a comprehensive financial report (e.g., interim report) nor an announcement of a report’s publication. It is a general regulatory submission required by the exchange, so it falls under the Regulatory Filings category.
2026-05-11 Chinese
115年4月營業收入
Regulatory Filings Classification · 10% confidence The provided text is clearly not a corporate filing but an error page stating the page cannot be accessed. It contains no references to any report, financial data, announcements, or regulatory content. By the fallback rule for documents that do not fit any specific category, it is classified as a general regulatory/other filing (RNS).
2026-05-11 Chinese
公告本公司115年第一季合併財務報告 董事會召開日期為115年05月05日
Report Publication Announcement Classification · 90% confidence The document is a brief announcement via Taiwan’s Market Observation Post System (公開資訊觀測站) stating the board meeting date and that the company will present its 115-year first quarter consolidated financial report. It does not include the financial data itself but merely notifies stakeholders of the upcoming report and meeting. This matches the definition of a Report Publication Announcement (RPA).
2026-04-27 Chinese
115年3月背書保證與資金貸與
Regulatory Filings Classification · 80% confidence The document is a routine regulatory disclosure from a Taiwanese listed company (“公開資訊觀測站”＝Market Observation Post System) detailing its fund lending and endorsement/guarantee balances. It is not a full financial report, earnings release, capital change notice, or management presentation. It is a standard regulatory filing that does not fit other specific categories, so it falls under the fallback “Regulatory Filings (RNS).”
2026-04-10 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.